Logo image of VERO

VENUS CONCEPT INC (VERO) Stock Fundamental Analysis

USA - NASDAQ:VERO - US92332W3034 - Common Stock

2.28 USD
-0.02 (-0.87%)
Last: 10/6/2025, 3:23:00 PM
Fundamental Rating

1

Overall VERO gets a fundamental rating of 1 out of 10. We evaluated VERO against 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VERO have multiple concerns. VERO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VERO has reported negative net income.
VERO had a negative operating cash flow in the past year.
VERO had negative earnings in each of the past 5 years.
VERO had a negative operating cash flow in each of the past 5 years.
VERO Yearly Net Income VS EBIT VS OCF VS FCFVERO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -65.52%, VERO is doing worse than 71.20% of the companies in the same industry.
With a Return On Equity value of -1776.32%, VERO is not doing good in the industry: 88.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -65.52%
ROE -1776.32%
ROIC N/A
ROA(3y)-47.85%
ROA(5y)-42.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VERO Yearly ROA, ROE, ROICVERO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

With a decent Gross Margin value of 64.88%, VERO is doing good in the industry, outperforming 68.59% of the companies in the same industry.
VERO's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for VERO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.88%
GM growth 5Y-0.33%
VERO Yearly Profit, Operating, Gross MarginsVERO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

VERO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VERO has been increased compared to 1 year ago.
Compared to 5 years ago, VERO has more shares outstanding
The debt/assets ratio for VERO has been reduced compared to a year ago.
VERO Yearly Shares OutstandingVERO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
VERO Yearly Total Debt VS Total AssetsVERO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

VERO has an Altman-Z score of -8.01. This is a bad value and indicates that VERO is not financially healthy and even has some risk of bankruptcy.
VERO has a Altman-Z score of -8.01. This is in the lower half of the industry: VERO underperforms 75.39% of its industry peers.
A Debt/Equity ratio of 6.82 is on the high side and indicates that VERO has dependencies on debt financing.
The Debt to Equity ratio of VERO (6.82) is worse than 88.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 6.82
Debt/FCF N/A
Altman-Z -8.01
ROIC/WACCN/A
WACC3.11%
VERO Yearly LT Debt VS Equity VS FCFVERO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

VERO has a Current Ratio of 1.10. This is a normal value and indicates that VERO is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of VERO (1.10) is worse than 87.43% of its industry peers.
VERO has a Quick Ratio of 1.10. This is a bad value and indicates that VERO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.71, VERO is not doing good in the industry: 87.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.1
Quick Ratio 0.71
VERO Yearly Current Assets VS Current LiabilitesVERO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

VERO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.91%, which is quite impressive.
The Revenue for VERO has decreased by -13.90% in the past year. This is quite bad
Measured over the past years, VERO shows a very negative growth in Revenue. The Revenue has been decreasing by -10.10% on average per year.
EPS 1Y (TTM)44.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.07%
Revenue 1Y (TTM)-13.9%
Revenue growth 3Y-15.01%
Revenue growth 5Y-10.1%
Sales Q2Q%-5.37%

3.2 Future

Based on estimates for the next years, VERO will show a very strong growth in Earnings Per Share. The EPS will grow by 39.60% on average per year.
Based on estimates for the next years, VERO will show a decrease in Revenue. The Revenue will decrease by -0.18% on average per year.
EPS Next Y77.14%
EPS Next 2Y39.6%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-9.41%
Revenue Next 2Y-0.18%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VERO Yearly Revenue VS EstimatesVERO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
VERO Yearly EPS VS EstimatesVERO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1K -2K -3K -4K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERO. In the last year negative earnings were reported.
Also next year VERO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERO Price Earnings VS Forward Price EarningsVERO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERO Per share dataVERO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as VERO's earnings are expected to grow with 39.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.6%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VERO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VENUS CONCEPT INC

NASDAQ:VERO (10/6/2025, 3:23:00 PM)

2.28

-0.02 (-0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners13.23%
Inst Owner Change0%
Ins Owners0.78%
Ins Owner Change0%
Market Cap4.24M
Analysts45.71
Price TargetN/A
Short Float %4.42%
Short Ratio2.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.91%
Min EPS beat(2)-21.43%
Max EPS beat(2)-20.38%
EPS beat(4)0
Avg EPS beat(4)-14.09%
Min EPS beat(4)-21.43%
Max EPS beat(4)-4.58%
EPS beat(8)0
Avg EPS beat(8)-30.66%
EPS beat(12)2
Avg EPS beat(12)-21.75%
EPS beat(16)3
Avg EPS beat(16)-28.76%
Revenue beat(2)1
Avg Revenue beat(2)0.46%
Min Revenue beat(2)-4.4%
Max Revenue beat(2)5.33%
Revenue beat(4)1
Avg Revenue beat(4)-5.75%
Min Revenue beat(4)-14.85%
Max Revenue beat(4)5.33%
Revenue beat(8)2
Avg Revenue beat(8)-5.83%
Revenue beat(12)4
Avg Revenue beat(12)-3.95%
Revenue beat(16)5
Avg Revenue beat(16)-4.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-3%
EPS NQ rev (3m)4.87%
EPS NY rev (1m)0%
EPS NY rev (3m)48.48%
Revenue NQ rev (1m)-1.42%
Revenue NQ rev (3m)-1.42%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)1.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.07
P/FCF N/A
P/OCF N/A
P/B 1.82
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-50.78
EYN/A
EPS(NY)-3.96
Fwd EYN/A
FCF(TTM)-10.15
FCFYN/A
OCF(TTM)-10.01
OCFYN/A
SpS32.32
BVpS1.25
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.52%
ROE -1776.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.88%
FCFM N/A
ROA(3y)-47.85%
ROA(5y)-42.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.88%
GM growth 5Y-0.33%
F-Score4
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 6.82
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.11%
Cap/Sales 0.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.1
Quick Ratio 0.71
Altman-Z -8.01
F-Score4
WACC3.11%
ROIC/WACCN/A
Cap/Depr(3y)4.54%
Cap/Depr(5y)6.03%
Cap/Sales(3y)0.23%
Cap/Sales(5y)0.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.07%
EPS Next Y77.14%
EPS Next 2Y39.6%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.9%
Revenue growth 3Y-15.01%
Revenue growth 5Y-10.1%
Sales Q2Q%-5.37%
Revenue Next Year-9.41%
Revenue Next 2Y-0.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year67.6%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.82%
OCF growth 3YN/A
OCF growth 5YN/A